Investing.com -- Baird upgraded DexCom Inc (NASDAQ:DXCM). to "Outperform" from "Neutral," citing progress in U.S. sales and upcoming catalysts. The price target was raised to $104 from $98.
DexCom's improved salesforce productivity and the potential for U.S. growth to return to low-to-mid teens by mid-2025 were key drivers. Recent advancements include earlier-than-expected progress on the G7 15-day sensor and potential FDA approval for hospital-based use.
The firm highlighted growing confidence in DexCom’s multi-year pipeline, including the G8 sensor, expected to bring advanced features like ketone monitoring by 2027. Expanding reimbursement for Type 2 diabetes patients is another tailwind.
Baird acknowledged competitive risks from Abbott's Libre 3 and potential Medicare repricing but expects DexCom to deliver revenue growth of 10-15% and EPS growth of 20% over the next 2-3 years.
With these factors, the stock’s valuation could rise to mid-20s multiples, Baird added.
Related Articles
Baird raises DexCom stock to outperform, target to $104
Luxury firms, chipmakers lift Europe's STOXX 600 to five-week high
Cuba releases jailed dissident, rights activist Jose Daniel Ferrer
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。